# AMPLATZER Duct Occluder II Additional Sizes

Study · id `cardio:ct-nct03055858` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03055858](<https://clinicaltrials.gov/study/NCT03055858>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03055858

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

## Technical summary

Registry record NCT03055858. Allocation not applicable; no masking; primary purpose treatment. Start 2017-06-05 (actual); primary completion 2019-09-25 (actual). Results posted on 2020-10-05.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT03055858, source copy `cardio:ctgov-nct03055858-2025-02-11`, retrieved 2026-10-26)
- Started: 2017-06-05 (actual) (ClinicalTrials.gov record NCT03055858, source copy `cardio:ctgov-nct03055858-2025-02-11`, retrieved 2026-10-26)
- Primary completion: 2019-09-25 (actual) (ClinicalTrials.gov record NCT03055858, source copy `cardio:ctgov-nct03055858-2025-02-11`, retrieved 2026-10-26)
- Completion: 2022-04-05 (actual) (ClinicalTrials.gov record NCT03055858, source copy `cardio:ctgov-nct03055858-2025-02-11`, retrieved 2026-10-26)
- Results first posted: 2020-10-05 (ClinicalTrials.gov record NCT03055858, source copy `cardio:ctgov-nct03055858-2025-02-11`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03055858, source copy `cardio:ctgov-nct03055858-2025-02-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03055858-2025-02-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: AMPLATZER Duct Occluder II Additional Sizes
- Acronym: ADO II AS
- Condition: Patent Ductus Arteriosus
- Intervention (Device): ADO II AS (PDA closure)
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: 19fb927ffb723e915f9abb7fd6a69dcaa89784041811787233d788f2f00ba5e1
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
